# Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)

> **NCT07193953** · PHASE1 · RECRUITING · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 6 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- ALS

## Interventions

- **DEVICE:** Next Generation Dome Helmet Focused Ultrasound
- **DRUG:** Intravenous immunoglobulin (IVIG), 10% solution for infusion
- **DRUG:** Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension

## Key facts

- **NCT ID:** NCT07193953
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07193953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07193953, "Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07193953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*